James Hippel - Nov 1, 2021 Form 4 Insider Report for BIO-TECHNE Corp (TECH)

Role
Chief Financial Officer
Signature
/s/ Brenda S. Furlow, Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed.
Stock symbol
TECH
Transactions as of
Nov 1, 2021
Transactions value $
-$3,621,789
Form type
4
Date filed
11/3/2021, 05:29 PM
Previous filing
Nov 1, 2021
Next filing
Aug 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TECH Common Stock Options Exercise $1.1M +8.82K +82.03% $125.05 19.6K Nov 1, 2021 Direct
transaction TECH Common Stock Sale -$1.87M -3.57K -18.22% $525.61* 16K Nov 1, 2021 Direct F1, F2
transaction TECH Common Stock Sale -$1.52M -2.88K -17.99% $526.50* 13.1K Nov 1, 2021 Direct F1, F3
transaction TECH Common Stock Sale -$756K -1.43K -10.91% $527.50* 11.7K Nov 1, 2021 Direct F1, F4
transaction TECH Common Stock Sale -$498K -943 -8.06% $528.55* 10.8K Nov 1, 2021 Direct F1, F5
transaction TECH Common Stock Options Exercise $25K +200 +1.86% $125.05 11K Nov 2, 2021 Direct
transaction TECH Common Stock Sale -$105K -200 -1.83% $525.10* 10.8K Nov 2, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TECH Stock Options (Right to Buy) Options Exercise $0 -8.82K -15.64% $0.00 47.6K Nov 1, 2021 Common Stock 8.82K $125.05 Direct F7
transaction TECH Stock Options (Right to Buy) Options Exercise $0 -200 -0.42% $0.00 47.4K Nov 2, 2021 Common Stock 200 $125.05 Direct F7
holding TECH Stock Options (Right to Buy) 18.1K Nov 1, 2021 Common Stock 18.1K $177.32 Direct F7
holding TECH Stock Options (Right to Buy) 24.1K Nov 1, 2021 Common Stock 24.1K $177.32 Direct F8
holding TECH Restricted Stock Units 3.94K Nov 1, 2021 Common Stock 3.94K Direct F6, F9
holding TECH Stock Options (Right to Buy) 19.9K Nov 1, 2021 Common Stock 19.9K $190.41 Direct F9
holding TECH Stock Options (Right to Buy) 26.6K Nov 1, 2021 Common Stock 26.6K $190.41 Direct F10
holding TECH Restricted Stock Units 3.22K Nov 1, 2021 Common Stock 3.22K Direct F6, F11
holding TECH Stock Options (Right to Buy) 14.4K Nov 1, 2021 Common Stock 14.4K $267.87 Direct F11
holding TECH Stock Options (Right to Buy) 19.1K Nov 1, 2021 Common Stock 19.1K $267.87 Direct F12
holding TECH Stock Options (Right to Buy) 8.33K Nov 1, 2021 Common Stock 8.33K $267.87 Direct F13
holding TECH Stock Options (Right to Buy) 8.33K Nov 1, 2021 Common Stock 8.33K $267.87 Direct F14
holding TECH Restricted Stock Units 1.95K Nov 1, 2021 Common Stock 1.95K Direct F6, F15
holding TECH Stock Options (Right to Buy) 7.6K Nov 1, 2021 Common Stock 7.6K $481.82 Direct F15
holding TECH Stock Options (Right to Buy) 10.1K Nov 1, 2021 Common Stock 10.1K $481.82 Direct F16
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $525.10 to $526.09, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $526.105 to $527.08, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $527.14 to $528.00, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $528.16 to $528.995, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
F7 Fully exercisable.
F8 Options to purchase 6,023 shares vest on 8/8/2019 and options to purchase 6,022 shares vest on each of 8/8/2020, 8/8/2021 and 8/8/2022.
F9 Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F10 Options to purchase 6,646 shares vest on 8/7/2020 and options to purchase 6,645 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.
F11 Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F12 Options to purchase 4,787 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023 and options to purchase 4,786 shares vest on 8/5/2024.
F13 Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
F14 Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
F15 Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F16 Options to purchase 2,534 shares vest on each of 8/6/2022 and 8/6/2023 and options to purchase 2,533 shares vest on each of 8/6/2024 and 8/6/2025.